{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:20:42Z","timestamp":1790806842973,"version":"4.1.0"},"reference-count":33,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Euro J of Neurology"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>In the Phase 3 MycarinG study (NCT03971422), rozanolixizumab improved myasthenia gravis (MG)\u2010specific outcomes versus placebo in patients with generalised MG, including those measured by the five independent MG Symptoms patient\u2010reported outcome (PRO) scales: Muscle Weakness Fatigability (MWF), Physical Fatigue (PF) and Bulbar Muscle Weakness (BMW) as secondary endpoints and Ocular Muscle Weakness and Respiratory Muscle Weakness (exploratory endpoints). This research aimed to provide further insights into these improvements.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p><jats:italic>Post hoc<\/jats:italic> analyses evaluated correlation (Pearson coefficient) between MG Symptoms PRO and subdomain scores of MG Activities of Daily Living (MG\u2010ADL) and Quantitative MG (QMG) at baseline. Proportions of responders reaching clinically meaningful thresholds and analyses at the item level (observed mean change and Rasch modelling of predicted change from baseline) are reported for MWF, PF, and BMW with rozanolixizumab versus placebo at Day 43.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Correlation coefficients between MG Symptoms PRO and MG\u2010ADL were strong (\u2265\u20090.7) for ocular and bulbar scores and moderate (0.5 to &lt;\u20090.7) for other scores. Correlations with clinician\u2010assessed QMG scores were generally weak (&lt;\u20090.5). For MWF, PF, and BMW, greater proportions of responders were observed with rozanolixizumab 7\u2009mg\/kg (46.9%, 31.3% and 26.6%, respectively) or 10\u2009mg\/kg (56.5%, 48.4% and 32.3%) versus placebo (28.1%, 26.6% and 10.9%). Item\u2010level analyses demonstrated rozanolixizumab benefit at a symptom\u2010specific level.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>MG Symptoms PRO scales correlate well with concepts in MG\u2010ADL while assessing additional concepts, such as PF and MWF. Results from the MG Symptoms PRO in MycarinG reflected improvements from baseline in patient\u2010relevant symptoms, including fatigue, with rozanolixizumab.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ene.70231","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T07:02:31Z","timestamp":1754290951000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Improvement in Patient\u2010Reported Symptoms of Generalised Myasthenia Gravis With Rozanolixizumab in the Randomised Phase 3 MycarinG Study Using the MG Symptoms PRO"],"prefix":"10.1111","volume":"32","author":[{"given":"Henry J.","family":"Kaminski","sequence":"first","affiliation":[{"name":"Department of Neurology &amp; Rehabilitation Medicine George Washington University  Washington District of Columbia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9270-5224","authenticated-orcid":false,"given":"Carlo","family":"Antozzi","sequence":"additional","affiliation":[{"name":"Neuroimmunology and Muscle Pathology Unit, Multiple Sclerosis Center Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Neurologico Carlo Besta  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3432-9747","authenticated-orcid":false,"given":"Ali A.","family":"Habib","sequence":"additional","affiliation":[{"name":"MDA ALS &amp; Neuromuscular Center, Department of Neurology University of California Irvine  Orange California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Pascuzzi","sequence":"additional","affiliation":[{"name":"Neurology Department Indiana University School of Medicine, Indiana University Health  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Sacconi","sequence":"additional","affiliation":[{"name":"Universit\u00e9 C\u00f4te d'Azur, Peripheral Nervous System &amp; Muscle Department Pasteur 2 Hospital, Centre Hospitalier Universitaire de Nice  Nice France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimiaki","family":"Utsugisawa","sequence":"additional","affiliation":[{"name":"Department of Neurology Hanamaki General Hospital  Hanamaki Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Vissing","sequence":"additional","affiliation":[{"name":"Copenhagen Neuromuscular Center, Department of Neurology Rigshospitalet, University of Copenhagen  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Regnault","sequence":"additional","affiliation":[{"name":"Modus Outcomes  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asha","family":"Hareendran","sequence":"additional","affiliation":[{"name":"UCB  Slough UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Grimson","sequence":"additional","affiliation":[{"name":"UCB  Slough UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tha\u00efs","family":"Taranc\u00f3n","sequence":"additional","affiliation":[{"name":"UCB  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5805-4883","authenticated-orcid":false,"given":"Vera","family":"Bril","sequence":"additional","affiliation":[{"name":"Ellen and Martin Prosserman Centre for Neuromuscular Diseases, Toronto General Hospital University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the MycarinG study investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0079-y"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI179742"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00145-3"},{"issue":"10","key":"e_1_2_9_5_1","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.538","article-title":"Fatigue in Myasthenia Gravis: Risk Factors and Impact on Quality of Life","volume":"6","author":"Hoffmann S.","year":"2016","journal-title":"Brain and Behavior: A Cognitive Neuroscience Perspective"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2020.06.010"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26069"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-02064-0"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-021-00285-w"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10891-1"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-022-00408-x"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/17562864231213240"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12209-3"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2018.01.006"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.7.1487"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1998.tb11015.x"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27837"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-023-00464-x"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1368525"},{"key":"e_1_2_9_20_1","unstructured":"U.S. Food & Drug Administration \u201cPatient\u2010Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims Guidance for Industry \u201dhttps:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/patient\u2010reported\u2010outcome\u2010measures\u2010use\u2010medical\u2010product\u2010development\u2010support\u2010labeling\u2010claims accessed: November 2024."},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.06.014"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.06.013"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00077-7"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51121"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16098"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjem.2018.08.001"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2012.06817.x"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-150082"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2012.06812.x"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23260"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjx179"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-018-8995-4"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31827f07be"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-019-02148-2"}],"container-title":["European Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ene.70231","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T06:51:46Z","timestamp":1756363906000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ene.70231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1111\/ene.70231"],"URL":"https:\/\/doi.org\/10.1111\/ene.70231","archive":["Portico"],"relation":{},"ISSN":["1351-5101","1468-1331"],"issn-type":[{"value":"1351-5101","type":"print"},{"value":"1468-1331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"2025-01-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70231"}}